Gebhard C, Stmpfli SF, Gebhard CE, Akhmedov A, Breitenstein A, Camici GG, et al
Over a 90-day period, the subjects were split into groups, being given either dosages of ALCAR or a placebo, twice per day
What research developments are needed to advance clinical use of these peptides
CJC-1295 (No DAC) Peptide and Growth Hormone Pulsatility While no studies directly investigate the potential of CJC-1295 no DAC (tetrasubstituted GRF 1-29), some researchers have conducted extensive experimentations with partially modified versions of GRF 1-29
Excess fat tissue increases estrogen levels while reducing testosterone, both of which can impair sperm production